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State-of-the-art treatment strategies have drastically ameliorated the outcome of patients affected by cancer. However, resistant
and recurrent solid tumors are generally nonresponsive to conventional therapies. A central factor in the sequence of events
that lead to cancer is an alteration in antitumor immune surveillance, which results in failure to recognize and eliminate the
transformed tumor cell. A greater understanding of the dysregulation and evasion of the immune system in the evolution and
progression of cancer provides the basis for improved therapies. Targeted strategies, such as T-cell therapy, not only generally
spare normal tissues, but also use alternative antineoplastic mechanisms that synergize with other therapeutics. Despite
encouraging success in hematologic malignancies, adaptive cellular therapies for solid tumors face unique challenges because
of the immunosuppressive tumor microenvironment, and the hurdle of T-cell trafficking within scarcely accessible tumor sites.
This review provides a brief overview of current cellular therapeutic strategies for solid tumors, research carried out to increase
efficacy and safety, and results from ongoing clinical trials.
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Introduction
Resistant, metastatic, or recurrent solid tumors represent unmet
clinical challenges, since they are seldom surgically resectable,
and largely nonresponsive to radiation and chemotherapy.
Relapse and chemoresistance are generally due to cancer cells
endowed with stem-like features (CSC) [1], which persist in com-
plex cellular niches that provide a unique microenvironment to
protect and promote CSC survival, self-renewal, maintenance,
and migratory ability [2].
Modern medical innovations simultaneously try to address
tumor heterogeneity in space and over time—including cancer
stem cell recognition and eradication—and to initiate, stimulate
or amplify a clinically meaningful antitumor immune response.
Tumor cells develop multiple mechanisms to evade immune rec-
ognition, including downregulation of tumor antigens, gener-
ation of an immunosuppressive microenvironment though
secretion of anti-inflammatory cytokines and expression of nega-
tive immune regulators able to silence immune effectors [3].
ATCT was introduced and tested in the field of solid tumors;
however, it has produced only sporadic responses. This standstill
is attributable to limitations in the understanding of tumor biol-
ogy and interactions with its microenvironment. In addition,
techniques used to identify, isolate, and amplify immune effector
cells have not been amenable to manufacturing processes that
comply with industry standards. Considerable progress has been
made along these two avenues: improved knowledge of cancer
immune evasion mechanisms and host–tumor interactions have
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led to the development of immune checkpoint inhibitors, which
are lead products for immune modulation in vivo.
Simultaneously, considerable technical refinements have opened
new prospects for the development of immune cell-based medi-
cinal products [4–6], as recently exemplified by the unprecedent-
ed success with chimeric antigen receptor (CAR)-T cells targeting
B-cell hematologic malignancies [7–9].
Replicating these results in solid tumors is a major scientific
challenge, and may not be feasible to the extent observed with
CD19 positive malignancies. Hurdles include the difficulty of
identifying target antigens that are homogeneously expressed by
all tumor cells while absent on normal tissues, impairment of T-
cell trafficking to the tumor site, and limited T-cell persistence
and proliferation in a hostile tumor microenvironment that
favors immune escape. Emerging evidence suggests that control
of resistant or metastatic cancers will not be achieved with a single
therapeutic agent, but rather with combinations of conventional
and immunotherapeutic cancer treatments [10]. In this perspec-
tive, drugs that target immune checkpoints, such as the CTLA4-
B7 and the PD1-PDL1 pathways, have led to clinical benefits
across a number of different tumor types and may well represent
a sort of adjuvant backbone facilitating response to ATCT [11].
Here, we focus on the description of ATCT starting from early
experiments and extending to more recent approaches based on
gene modification, with the aim of overcoming immune evasion
to pave the way for effective solid tumor control.
T cells and tumor recognition
To understand how ATCT contributes to cancer immune surveil-
lance, it is important to get insight into the basics of tumor recog-
nition. Maturation of T cells occurs within the thymus, where the
T-cell receptor (TCR) repertoire is shaped by somatic gene re-
arrangement and selection processes, resulting in a T-cell pool
characterized by limited reactivity to self but strong reactivity to
foreign antigens. The TCR does not bind directly to its antigen,
but recognizes a limited number of short peptides derived from
the antigen (epitopes), bound to major histocompatibility com-
plex class I (MHCI) or class II (MHCII) on the target cell surface.
Most cells express MHCI, which presents epitopes to CD8þ cyto-
toxic T lymphocytes (CTLs): lysis of cells expressing cognate epit-
opes in the context of MHCI is considered the main mechanism
responsible for antitumor immune surveillance. However, in re-
cent years, the role of CD4þ T cells, which recognize epitopes
complexed with MHCII on the surface of professional antigen-
presenting cells, has gained increasing attention, not only for
their helper function in sustaining CD8þ T-cell responses and
activating innate immunity, but also for direct killing of tumor
cells [12].
Adaptive cell therapy with natural T cells
endowed with antitumor activity
The modern era of ATCT began with the use of recombinant
human interleukin-2 (rhIL-2) in the treatment of melanoma and
renal cell cancers, and the observation that this cytokine was able
to favor human T-cell growth in vitro. This led to the first clinical
applications of cytokine-induced immune effector cells, gener-
ated from patients’ lymphocytes in the presence of high-dose
rhIL-2. Objective clinical responses were reported [13], and al-
though these could not be dissociated from the effects of the co-
infusion of high-dose rhIL-2, they provided the basis for clinical
evaluation of tumor-specific T cells obtained by in vitro culture
(Figure 1).
Tumor-infiltrating lymphocytes
T cells directed to tumor-associated antigens (TAA) generally in-
filtrate tumor tissue, represent a biomarker associated with
improved prognosis in some instances and may be extracted,
expanded ex vivo in the presence of homeostatic cytokines, and
reinfused into patients. Evidence that transferred T cells can
eradicate cancer in humans comes from the success of ATCT
with cultured lymphocytes isolated from tumor biopsies (TILs)
in patients with melanoma [14–17]. The first trial, conducted at
the National Cancer Institute (NCI) on 20 patients with metastat-
ic disease, showed that transfer of expanded TILs and rh-IL2, pre-
ceded by a single dose of cyclophosphamide, could induce more
than 50% objective responses including a complete response
(CR) with minimal toxicity [13]. Since this preliminary report,
results in melanoma have further improved through the opti-
mization of TIL expansion protocols and preparative regimens,
combining fludarabine with cyclophosphamide chemotherapy,
and testing different doses of total body irradiation, successfully
doubling the CR rate to 24% [15, 18]. The importance of lym-
phodepleting chemotherapy, highlighted in the melanoma set-
ting, has also been crucial for CAR-T-cell therapy protocols [7,
19]. Although TILs could be demonstrated in other solid tumors,
their expansion and in vivo efficacy did not reach the success of
melanoma treatment, experienced in hundreds of patients treated
at the NCI [5] and recently duplicated by other groups [20, 21],
and by a multicenter phase II study that is currently being
expanded for registration purposes [22]. Recently, preliminary
data showing objective responses and CRs were reported for chol-
angiocarcinoma (CCA) [23] and cervical cancer [24], and a num-
ber of clinical trials are currently ongoing to test ATCT with TILs
in gastrointestinal, gynecological, head and neck, breast and lung
cancers.
Virus-specific cytotoxic T lymphocytes
Among T cells targeting antigens through their native receptors,
CTLs directed to viral antigens, obtained by in vitro culture in the
presence of virus-derived TAA, have also been extensively used
[25]. Epstein–Barr virus (EBV)-specific T cells expanded from
the hematopoietic stem cell donor have been demonstrated to
prevent and treat virus-associated lymphoproliferative diseases
[26–28]. Autologous EBV-specific CTLs, which have shown anti-
tumor activity in patients with less immunogenic hematologic
malignancies, such as Hodgkin or non-Hodgkin lymphoma [29,
30], have also been successfully employed in the treatment of
EBV-associated solid tumors, such as nasopharyngeal carcinomas
(NPC) [31–35]. More than 80 NPC patients treated with autolo-
gous EBV-targeted ATCT for recurrent, metastatic disease, have
so far been reported, with a promising 20% objective response
rate, including 10% CR. Attempts to enhance T-cell survival,
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trafficking and effector function by administering a lymphode-
pleting preparative regimen, based on the melanoma TIL therapy
experience, did not improve outcomes in this clinical setting [33,
34]. In line with EBV ATCT, cytomegalovirus-specific CTLs have
been explored in clinical trials for glioblastoma [36], and human
papilloma virus (HPV)-directed TILs have been successfully
employed in HPV-associated malignancies [24].
T cells targeting other TAA
For tumors not associated with viruses, several classes of TAAs
have been explored as potential targets [37]. These include anti-
gens that are mostly non-tumor-selective, as they are found in
normal tissues but overexpressed on tumors, or expressed only
during fetal development or in immune-privileged sites such as
testes. T cells targeting these TAAs may potentially attack healthy
tissues expressing even low-level antigen, causing severe adverse
events, referred to as on-target off-tumor toxicities, when an es-
sential organ is involved. With recent advances in genomic
technologies, a quest for mutational and transcriptional tumor
profiles was embraced, in order to identify optimal personalized
targeted therapies. While the majority of mutant gene products
are not targetable with the currently available pharmaceuticals,
the genetic sequencing approach has allowed the identification of
neoantigens generated by gene rearrangements or mutations [38].
Genomic studies suggest how the latter may be the main target
antigens underlying the success of therapy with immune check-
point inhibitors or TILs [39, 40]. Indeed, when compared with
non-mutated self-antigens, the T-cell pool available for these anti-
gens should not be affected by central T-cell tolerance. Shared
hot-spot mutations of driver oncogenes are more likely to be
expressed by all cells within a tumor as well as across tumor sam-
ples and histologies, and identification of TCRs targeting these
neoantigens may be used as off-the-shelf reagents for TCR gene
therapy. Moreover, their use is likely to limit the risk of on-target
off-tumor toxicity. A proof of principle for the potential in vivo ef-
ficacy of T cells that target tumor neoantigens arising from cancer
mutations has been provided in the setting of solid tumors [41].
1.   TIL EXPANSION FROM TUMOR TISSUE
2.   EX VIVO EXPANSION OF TAA-SPECIFIC T CELLS
3.   GENETIC MODIFICATION
TUMOR-SPECIFIC 
T CELLS
TILs are isolated from resected tumor tissue, selected and expanded to large numbers by 
culture in the presence of rhIL-2
Peripheral blood T cells are stimulated by specific TAA recognition on antigen-presenting cells, and 
expanded to large numbers by culture in the presence of homeostatic cytokines
Peripheral blood T cells are activated, and their activity is redirected by insertion of TCR or CAR 









Figure 1. ATCT for solid tumors: manufacturing strategies. T cells derived from tumor resection tissue or peripheral blood are manipulated
according to the illustrated approaches, in order to manufacture tumor-directed cellular products for ATMP. IL-2, recombinant human inter-
leukin-2; ILs, interleukins; TAA, tumor-associated antigens; CAR, chimeric antigen receptors.
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Adaptive cell therapy with engineered T
cells: the era of CARs
ATCT with TILs/CTLs has been mostly successful in cancers
characterized by strong immunogenicity due to high frequency of
mutational events [38]. The targeting of cancers such as pediatric
solid malignancies or other frequent tumors, such as breast or
prostate cancer, for which neoantigens generated by non-
synonymous mutations are limited, is a more daunting task.
Indeed, TAA are mostly overexpressed self-antigens, and, as such,
subject to tolerance. In addition, TAA recognition by T cells is
MHC-restricted, and the majority of solid tumors downregulate
MHC expression as an immune escape mechanism. In order to
overcome these hurdles, genetically engineered T cells have
emerged as an alternative to TILs and CTLs (Figure 1).
Genetic retargeting has been obtained by means of two different
approaches: (i) transfer of natural tumor-specific TCRs isolated
from high-avidity T cells that recognize cancer antigens [42] and (ii)
transfer of synthetic TCRs, also referred to as CARs [43] (Figure 2).
T cells engineered with natural TCRs
TCR therapy trials have mostly targeted overexpressed self/tumor
antigens also expressed by healthy adult cells, such as gp100 and
Melan-A/MART-1, or oncofetal antigens, present on healthy cells
exclusively during fetal development, and ectopically expressed
in tumors, such as NY-ESO-1 and MAGE. Autologous T cells
retrovirally transduced with a TCR specific for NY-ESO-1 resulted
in objective clinical responses in 61% of patients with synovial cell
sarcoma and 55% of patients with melanoma [44, 45], and one of
three patients treated with autologous T cells engineered to ex-
press a TCR against human carcinoembryonic antigen (CEA) had
an objective regression of metastatic colorectal cancer (CRC) [46].
The rate of objective responses obtained in melanoma patients did
not significantly differ from those obtained in clinical trials evalu-
ating TILs, but fewer sustained CRs were observed. These data are
likely due to inherent limitations of TCR biology. In particular,
HLA-restricted specificity limits the fraction of potential patients
to those expressing the relevant HLA allele recognized by T cells,
and clinical efficacy is dependent upon TCR affinity and the ex-
pression of MHC-antigen complexes on the tumor cell surface
[42]. The transferred and endogenous TCRs compete for CD3
binding, resulting in mutual receptor dilution and lower antitu-
mor efficacy. Moreover, the a and b chains of the endogenous
TCR may mispair with the respective chains of the transferred
TCR, forming hybrid receptors with unpredictable and potentially
detrimental specificities. Furthermore, targeting of antigenic spe-
cificities that are expressed at low level on normal tissues has led to
severe on-target off-tumor toxicity [47, 48].
T cells engineered with CARs
In order to circumvent the challenges posed by antigen escape






























Figure 2. Structure of endogenous TCR, engineered TCR and CAR receptors. In first generation CARs, the variable heavy and light single-
chains (antigen-binding moiety) are linked by a spacer to the transmembrane region, usually derived from CD28. The intracellular domain
includes the CD3f signaling pathway machinery, which activates the T cell in response to the specific tumor antigen binding. In second and
third generation CARs, co-stimulatory domains, such as CD28 and/or 4-1BB, are added to improve antitumor potency, cytokine production,
and persistence of the T cell. MHC, major histocompatibility complex; TAA, tumor-associated antigen; CoDomain, costimulatory domain.
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CARs, constructed by fusing an antigen-binding domain that is
derived from a single-chain variable fragment of a monoclonal
antibody against a tumor surface antigen, to a flexible spacer re-
gion, a trans-membrane domain and the TCR intracellular do-
main, traditionally consisting of the CD3 zeta (f) chain, capable
of activating T cells. As the antigen-directed exodomain binds
directly to target cell surface epitopes, CAR recognition of tumor
target cells is HLA-unrestricted, thus resistant to tumor escape
mechanisms related to HLA downmodulation and altered proc-
essing. Initial trials with CAR-T cells targeting solid and hemato-
logic tumors showed limited clinical results, with poor in vivo
expansion and duration [49–52]. In the setting of solid tumors,
the unique exception was CAR-T-cell therapy targeting the
disialo-ganglioside GD2, which induced complete remission in 3/
11 pediatric patients with neuroblastoma [53].
CAR-T-cell therapy in hematologic malignancies. Progressive
improvements in the design of CARs have led to second and third
generation molecules (Figure 2), that incorporate one or two
additional costimulatory domains, such as CD28, 4-1BB and
OX40, which enhance killing activity and expansion potential
(CD28), as well as in vivo persistence (4-1BB), resulting in dra-
matic results in hematologic malignancies [54–61], with 81% 3-
month remission rate and 50% event-free survival at 12 months
in a phase II global multicenter clinical trial with CD19-CAR-T
cells in children and young adults treated for acute lymphoblastic
leukemia [61].
In every trial, efficacy correlated with the expansion of CAR-T
cells, and relapses were due to immune escape mechanisms, such
as targeted antigen loss or development of immunity directed to
the CAR molecule mouse portion [58, 59]. The increase in CAR-
T-cell clinical efficacy, however, was paralleled by the potential to
induce severe adverse events, such as cytokine release syndrome
(CRS), neurological toxicity, and on-target off-tumor toxicities
[57–62]. While still within the field of lymphoid malignancies,
the fast-growing experience when treating multiple myeloma
patients with CAR-T cells targeting BCMA suggests that the in-
tensity of side-effects may vary depending on the targeted tumor
antigen, and that side-effects may be manageable even in an older
population [63–65]. To date, two autologous CAR-T cells target-
ing CD19 have been approved by FDA and EMA for the treat-
ment of patients with refractory/relapsed ALL or high-grade
B-NHL. Since the two medicinal products benefited from the fast
track procedure, the number of patients that contributed data
were relatively small; thus, additional data obtained in ‘real-life’
practice after long-term follow up are needed to fully appraise
their clinical utility.
CAR-T-cell therapy in solid tumors. On the basis of results
obtained in hematologic malignancies, a number of trials have
been started to test the efficacy of CAR-T cells in solid tumors
(supplementary Table S1, available at Annals of Oncology online).
To date, however, clinical results in this setting have been much
less encouraging, with a general lack of therapeutic response and
presence of on-target off-tumor toxicity. However, some studies
have achieved promising outcomes that justify further explor-
ation of this approach in solid tumors. The group at Baylor
College of Medicine pioneered the use of GD2-specific CAR-T
cells for neuroblastoma [53, 66]. In a trial of 19 patients with
high-risk neuroblastoma, 3 had a CR to CAR-T-cell infusion,
with only local pain and slight fever as adverse events [53, 66].
The same group evaluated the safety and antitumor activity of
second-generation CD28f HER2-specific CAR-modified virus-
specific T cells in patients with progressive glioblastoma
multiforme (GBM). The results showed that CAR-T cells are well
tolerated, with no dose-limiting toxic effects, and can produce
objective responses, as one patient showed a PR for more than
9 months, and seven patients had SD lasting several months [67].
Other clinical trials have demonstrated the feasibility and safety
[68] and clinical efficacy [69] of second-generation EGFRvIII-
specific and IL13BBf-specific CAR-T cells, respectively, in
patients with refractory GBM.
Investigators at the University of Pennsylvania explored an ap-
proach based on mRNA-transduced CAR-T cells that target mes-
othelin (CART-meso) in patients with advanced malignant
pleural mesothelioma or advanced pancreatic cancer. In the first
two patients reported, CART-meso cells showed some antitumor
activity in vivo, in the absence of distinct toxicities [70].
Second-generation CAR-T cells specific for epidermal growth
factor receptor (EGFR) were employed in a phase I study that
treated 11 patients with advanced non-small-cell lung cancer,
obtaining 2 PR and 5 SD lasting from 2 to 8 months, with limited
adverse events including skin toxicity, nausea, vomiting, dyspnea
and hypotension [71]. EGFR-CAR-T cells were also applied by
the same investigators in the treatment of one patient with refrac-
tory, metastatic CCA, demonstrating a PR lasting more than
1 year. However, the objective response was accompanied by epi-
dermal and endothelial toxicity [72]. A clinical trial of CEA CAR-
T therapy in 10 patients with metastatic CRC achieved SD in 7
patients who were in progression after previous treatments, with-
out severe adverse events related to CAR-T therapy [73]. Similar
to these experiences, second-generation HER2-specific CAR-T
cells, used in a phase I clinical trial conducted on 19 patients with
refractory HER2-positive sarcoma, could induce SD lasting from
12 weeks to 14 months in 4 assessable patients [74].
Toxicity of CAR-T-cell therapy. Various toxicities were observed
after CAR-T-cell infusion in solid tumors. In the setting of hema-
tologic malignancies, CRS is a frequent, potentially severe adverse
event of CAR-T-cell therapy. The release of pro-inflammatory
cytokines by the infused cells induces monocyte and macrophage
activation that can lead to multiple organ failure. Currently, this
complication is managed by cytokine level assessment and early
administration of the anti-IL6R monoclonal antibody tocilizu-
mab. However, CRS, as well as the neurological toxicity some-
times observed in the hematologic setting, is not a common event
after CAR-T-cell therapy for solid tumors, possibly since the
tumor load is lower. Conversely, trials conducted in solid tumor
cohorts with CAR-T cells produced critical, unexpected on-target
off-tumor toxicities, resulting from the recognition by CAR-T
cells of TAA expressed on healthy tissues [75, 76]. Some antigens
specific to tumors have been identified that result in more limited
off-tumor effects, but many of these targets have mediated poor
clinical efficacy. Moreover, as for hematologic malignancies, solid
tumors undergo antigen escape due to selection pressure favoring
tumor cells lacking the targeted antigen. Strategies to increase
tumor selectivity while sparing healthy tissues are being evaluated
to control on-target off-tumor toxicity.
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Improving safety and efficacy of T-cell
therapy for solid tumors
A significant amount of research has focused on enhancing
the activated T-cell response against tumor cells, promoting
their in vivo expansion, and improving their persistence in
the host. Interventions encompass genetic modifications to in-
crease T-cell affinity or avidity [77, 78] or to induce cytokine
production [79–81], and selection of specific T-cell subsets
[82, 83]. Regarding the choice of genetic modification vehicle,
so far retroviral gene transfer vectors have been mostly used
in CAR-T-cell trials, as they have the advantage of inducing
high-level stable transduction in stimulated human T cells.
However, immunogenicity and insertional mutagenesis, to-
gether with the costs due to viral vector production and use,
has led to explore alternative methods, such as lentiviral vec-
tors, that do not require cell cycling induction and cause very
limited immune and inflammatory responses, or the use of
gene transfer forms that do not depend on costly viral vector
production, such as transposons, or the non-integrating sys-
tems like designer nucleases, DNA plasmids or RNA transfer
[52, 57, 84, 85]. Strategies to enhance affinity to self-antigens
have increased efficacy, but also led to unexpected severe off-
target toxicity, when previously unknown cross-reactivity was
observed with epitopes derived from unrelated proteins
expressed by normal tissues [48].
T-cell migration and intra-tumor trafficking
The first hurdle encountered by T cells when targeting solid
malignancies is the difficulty in migrating to and adequately pen-
etrating the tumor. Solid cancers may evade immune surveillance
by secreting chemokines which inhibit T-cell migration into the
tumor [86]. Several different chemotherapeutics have been
shown to induce chemokines and chemokine ligands [87], and
their incorporation into a combined treatment approach with T
cells may enhance CD8þ T-cell recruitment and reduce tumor
growth. Alternatively, CAR-T cells may be modified to express
chemokines that enhance their intra-tumor trafficking [88]. It
has been shown that the forced expression of chemokine CCR2
on CAR-T cells targeting GD2 in neuroblastoma enhances T-cell
infiltration and augments the antitumor activity of the trans-
ferred cells [89]. In addition, T cells migrating to the tumor may
be hindered by a physical barrier of fibrotic extracellular matrix
produced by tumor fibroblasts and myeloid cells. As loss of hep-
aranase, an enzyme that contributes to degradation of extracellu-
lar matrix, has been observed in T cells after in vitro culture, its
overexpression in CAR-T cells can enhance T-cell infiltration
[90]. Alternatively, targeting the surrounding non-malignant
stroma using CAR-T cells may be an option [91].
Tumor microenvironment repolarization
The complex immunosuppressive tumor microenvironment,
and the segregation of tumor cells in areas that may be diffi-
cult to access, are other major hurdles to the efficacy of
ATCT. Factors that negatively regulate T-cell activity and fa-
cilitate tumor immune evasion include tumor-resident regula-
tory T cells and myeloid-derived suppressor cells, as well as
the presence of cytokines such as IL-10, transforming growth
factor beta, vascular endothelial growth factor, and prosta-
glandin E2. Additionally, negative feedback is provided by sig-
naling through the programmed death-1 (PD-1) and CTLA-1
pathways (Figure 3A).
T-cell arming. To repolarize the tumor microenvironment and
fully restore the effector function of transferred T cells, preclinical
studies have tested the feasibility of conferring resistance to im-
munosuppressive molecules [92], or the ability to deliver cyto-
kines to either activate host effectors or hinder host suppressors
[79–81, 93], or coupling CAR-T cells with switch receptors inter-
fering with the inhibitory signal provided by immune check-
points [94] (Figure 3B). The cytokine-producing ‘TRUCKs’ (T
cells Redirected for Universal Cytokine Killing) [95] significantly
enhanced efficacy of MUC-16ecto CAR against a preclinical model
of ovarian carcinoma [96], and are currently being tested in phase
I clinical trials.
Combination of T-cell therapy with checkpoint inhibitors. In add-
ition to T-cell arming, an approach that combines ATCT with
immune checkpoint inhibitors, antitumor agents that act by
releasing the ‘brakes’ on pre-existing tumor-reactive T cells and
facilitate generation of new T-cell responses, may represent a
strategy to improve the activity and tumor killing by T-cell gener-
ated ex vivo [97–99] (Figure 3B). Recent positive experiences
have been observed in refractory hematologic malignancies with
CD19 CAR-T cells combined with the PD-1 blocking agent pem-
brolizumab [100, 101]; similar strategies are being investigated in
solid tumors [102].
Increasing T-cell therapy safety
Solid tumors typically exhibit a heterogeneous pattern of TAA,
promoting antigen escape. Thus, identifying patient-specific,
tumor-specific mutated antigens [41, 103], potentially present
also in cancer types that exhibit low-level immunogenicity, may
help develop treatments for multiple cancer types so far not
amenable to ATCT, and limit toxicity. Despite these advances in
targeting, toxicity may still ensue. In order to limit severe conse-
quences, strategies aimed at hampering an unwanted off-target
T-cell response are being investigated. Recently, a pharmacologic
on/off switch based on the use of the tyrosine kinase inhibitor
dasatinib has been investigated [104].
Suicide gene insertion. The introduction of suicide genes may
help remove undesirable toxicity [105, 106]. The first attempt at
introducing suicide genes into T cells involved the use of HSV-
thymidine kinase, which converts ganciclovir into a toxic metab-
olite, and proved effective in controlling graft-versus-host disease
(GvHD) in several trials [105, 107]. However, the lytic response
observed was slow, and the viral proteins may stimulate immuno-
genicity. More recently, the inducible-caspase 9 system was
designed and tested. It is based on the expression of a monomeric
iCasp9 domain that dimerizes upon administration of a small
molecule, leading to cleavage of caspase 3 and apoptosis of T cells
[106]. Alternatively, in the case of CAR-T cells, incorporating
epitopes like RQR8/CD20 into the CAR construct provides a tar-
get for their depletion with antibodies such as rituximab [108].
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Specificity enhancement. Other strategies have been devised to in-
crease CAR-T-cell specificity, and, therefore, limit toxicity. One
approach is based on T-cell modification with two different
CARs, one containing the CD3f signaling domain to activate T-
cell function, and the other providing the co-stimulation signal
by CD28 and/or CD137 [109–111]. Full CAR-T-cell activation
and function are only achieved in the context of the presence of
both antigens, an unlikely occurrence in the case of cells from
normal tissue. Another strategy to obtain differential recognition
of malignant and normal cells is based on affinity-tuned CAR-T
cells that activate T cells based on the density of target antigen ex-
pression. Two independent studies demonstrated that a CAR-T
cell with reduced affinity rendered T cells preferentially activated
by a high, but not low, density of target antigen [112, 113].
Widening T-cell therapy access
Despite the therapeutic potential of ATCT, logistics and regula-
tory hurdles have limited translation into commercially available





































































Figure 3. Summary of interventions to overcome the immunosuppressive tumor microenvironment and enhance T-cell efficacy. Tumor cells
and suppressor cells (i.e. T-REGs; MDSCs) up-regulate inhibitory ligands, such as PD-L1 or CTLA-4, and secrete suppressive cytokines and fac-
tors (A). The use of checkpoint inhibitor agents, or modification of CAR T cells to induce cytokine secretion (TRUCKs), expression of a domin-
ant negative (dn) TGFb-receptor or conversion of a negative IL-4 signal to a positive IL-7 signal (SWITCH CARs) are examples of strategies able
to help overcome tumor tolerance and restore tumor immunogenicity (B). CAR, chimeric antigen receptor; MDSC, myeloid-derived suppres-
sor cells; APC, antigen-presenting cells; T-REG: regulatory T cell; MHC, major histocompatibility complex; TAA, tumor-associated antigen; CPI,
checkpoint inhibitor; IL, interleukin; TGF-b, tumor growth factor-b; IFNc, interferon-c; dnTGF-bR, dominant negative TGFb-receptor; SWITCH
CAR, chimeric switch receptors; TRUCK, T cells redirected for universal cytokine killing.
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burdensome for academic institutions, although the new
European clinical trial regulation favors accelerated novel drug
evaluation and approval schemes to ensure early access to in-
novative therapies [114]. The majority of subjects treated to date
with ATCT have received autologous or allogeneic dedicated T
cells, but this approach may not be best suited for widespread
cost-effective delivery of cellular therapy, since these are person-
alized medicines that are produced on-demand through a com-
plex and costly supply chain, thus implying some delay in
manufacturing of the final product and the risk that the disease
will evolve and be fatal for candidate patients. Allogeneic ATCT,
including CAR-T cells, represent potential off-the-shelf products,
that could possibly be manufactured in small batches without the
need for tailored products. However, they carry the risk of im-
mune rejection by the host, and their short persistence may re-
quire additional therapies to consolidate responses, and could
potentially cause GVHD, although in preliminary clinical trials
de novo GVHD was not observed [115]. Gene editing offers the
prospect of addressing human leukocyte (HLA) barriers and the
development of universal T-cell therapies [113, 116, 117].
Recently, ‘off-the-shelf’ T cells modified using transcription
activator-like effector nucleases and expressing CD19 or CD123




The major obstacle to further development of ATCT in solid
tumors is the immunosuppressive environment. Strategies to
counteract these tolerogenic mechanisms will be required to fur-
ther enhance the efficacy of ATCT. In this scenario, T-cell ther-
apy, alone or in combination with immune checkpoint inhibitors
or other agents targeting either the cancer cell or the tumor envir-
onment, will likely play a role in improving cancer treatment out-
comes. Designing and selecting the most appropriate clinical
trials to rapidly identify combinatorial approaches that are effi-
cient in the different patient populations, and devising new and
sustainable reimbursement modalities or developing network
models for ATMP production in academic centers will add to the
many biological and medical challenges faced by the healthcare
and patients’ communities.
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